Bio-Path Holdings, Inc. (BPTH)
OTCMKTS
· Delayed Price · Currency is USD
0.1700
+0.0150 (9.68%)
Mar 31, 2025, 2:03 PM EST
Bio-Path Holdings Employees
Bio-Path Holdings had 10 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
10
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$989,400
Market Cap
668.43K
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 2,931 |
Elite Pharmaceuticals | 64 |
Glass House Brands | 413 |
Northwest Biotherapeutics | 25 |
CytoDyn | 9 |
Silence Therapeutics | 116 |
American Oncology Network | 1,525 |
Bio-Path Holdings News
- 3 days ago - Bio-Path GAAP EPS of -$4.12 - Seeking Alpha
- 3 days ago - Bio-Path Holdings Reports Full Year 2024 Financial Results - GlobeNewsWire
- 13 days ago - Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 6 weeks ago - ARMISTICE CAPITAL, LLC Acquires Significant Stake in Bio-Path Holdings Inc - GuruFocus
- 6 weeks ago - Bio-Path Holdings Provides Key Clinical Updates - GlobeNewsWire
- 6 weeks ago - Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Bio-Path Holdings Provides 2025 Clinical and Operational Update - GlobeNewsWire
- 3 months ago - Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity - GlobeNewsWire